BNB Plus Corp. (BNBX)
2.26
0.00 (0.00%)
USD |
NASDAQ |
Dec 19, 10:14
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.919M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -98.71% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.4047 |
| Price to Book Value | 0.4019 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.046 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY. |
| URL | http://www.adnas.com |
| Investor Relations URL | http://adnas.com/adnas_home/investors/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Dec. 25, 2025 (est.) |
| Last Earnings Release | Aug. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY. |
| URL | http://www.adnas.com |
| Investor Relations URL | http://adnas.com/adnas_home/investors/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Dec. 25, 2025 (est.) |
| Last Earnings Release | Aug. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |